PMC6234987_01
Contrast CT scans of the chest showing a left paravertebral mass at T1-2 level (indicated by a red circle) prior to use of alectinib (A and C) and resolution of this mass 14 weeks after initiating alectinib (B and D). Contrast CT scans of the chest showing decrease in size of the right pulmonary nodule (indicated by a red arrow) and significant improvement of the left lung aeration (indicated by a red star) 14 weeks after initiating alectinib (F and H) as compared with prior to use of alectinib (E and G).. Abbreviation: CT, computed tomography.
lctt-9-111Fig1.jpg
PMC6234987_01_lctt-9-111Fig1.jpg
f1-lctt-9-111
In April 2018, the patient developed dry cough while on crizotinib for which a contrast CT scan of the chest was performed that showed complete opacification of the left hemithorax (Figure 1). ALK inhibitor against T1151K. A follow-up contrast CT scan of the chest 14 weeks later showed a dramatic response (-76% by RECIST 1.1) including resolution of a 2.9 cm left paravertebral mass at T1-2 level, decrease in size of the right pulmonary nodule from 1.8 to 1.1 cm, and significant improvement of the left lung aeration (Figure 1).